Compare ISPC & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISPC | AEMD |
|---|---|---|
| Founded | 2009 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 2.1M |
| IPO Year | 2020 | 2008 |
| Metric | ISPC | AEMD |
|---|---|---|
| Price | $1.16 | $6.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 486.6K | ★ 2.7M |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,928,998.00 | N/A |
| Revenue This Year | $638.10 | N/A |
| Revenue Next Year | $17.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.51 |
| 52 Week High | $6.77 | $9.50 |
| Indicator | ISPC | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 27.64 | 73.01 |
| Support Level | $0.27 | $1.64 |
| Resistance Level | $1.94 | $9.50 |
| Average True Range (ATR) | 0.09 | 0.67 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 6.29 | 61.24 |
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.